Article Information
- Received August 10, 2024
- Revision received February 28, 2025
- Accepted March 16, 2025
- First published March 24, 2025.
Author Information
- Maria Mancini1,2,
- Takuya Hikima3,
- Paul Witkovsky3,
- Jyoti C. Patel2,3,
- Dominic W. Stone3,
- Alison H. Affinati4, and
- Margaret E. Rice1,2,3,*
- 1Department of Neuroscience and Physiology, NYU School of Medicine, New York, NY, USA
- 2Neuroscience Institute, NYU School of Medicine, New York, NY, USA
- 3Department of Neurosurgery, NYU School of Medicine, New York, NY, USA
- 4Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
- ↵*Correspondence should be addressed to Margaret E. Rice at margaret.rice{at}nyu.edu
Author contributions
Author contributions: M.M., T.H., P.W., J.P., and M.R. designed research; M.M., T.H., P.W., D.S., and A.A. performed research; M.M., T.H., P.W., J.P., and M.R. analyzed data; M.M., T.H., P.W., and M.R. edited the paper; M.M. and M.R. wrote the paper; A.A. contributed unpublished reagents/analytic tools.
Disclosures
The authors declare no competing financial interests.
Funding was provided by the Marlene and Paolo Fresco Institute for Parkinson’s Disease and Movement Disorders, including a postdoctoral fellowship to M.M., and by National Institutes of Health grants DA050165 (M.E.R.) and DK122660 (A.H.A.). We are grateful to Martin G. Myers Jr. at the University of Michigan for providing LepRbEGFP mice utilized in this study, to Adam C. Mar at the NYU Grossman School of Medicine for advice on the locomotor experiments, and to Riccardo Melani for advice on statistical analyses.
Funding
HHS | NIH | National Institute on Drug Abuse (NIDA)
DA050165HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
DK122660
